Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 33 Publications

6 Customer Reviews

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NVrWRZR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW3WIdKSzVyPUCuNFI5ODZizszN NXTSVJY4W0GQR1XS
KS-1 NGfmPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17OWGlEPTB;MD6wN|g{PSEQvF2= MXXTRW5ITVJ?
TE-11 NI\0PZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvMTWM2OD1yLkC3PFIzKM7:TR?= NULHUXZVW0GQR1XS
EW-1 NX65elZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrzSFhuUUN3ME2wMlA5PTh3IN88US=> MUXTRW5ITVJ?
HMV-II MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEi4OFYh|ryP MkHxV2FPT0WU
COLO-205 M3LuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGizfmlKSzVyPUCuNVA1PTRizszN NFrGTVJUSU6JRWK=
ES1 M4[1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHQTWM2OD1yLkGwOlk3KM7:TR?= Ml[5V2FPT0WU
GDM-1 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLIUpdLUUN3ME2wMlE{Pjd{IN88US=> M4HkU3NCVkeHUh?=
ML-2 M2fp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfQN|JKSzVyPUCuNVU5QTZizszN MlnlV2FPT0WU
Saos-2 NX\pW4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7PeZh1UUN3ME2wMlE3PTJ4IN88US=> NGXlbHVUSU6JRWK=
NCI-H1355 M2PITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7vOWVZUUN3ME2wMlE5OTN3IN88US=> MXjTRW5ITVJ?
G-401 NX;4SVJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMUiyN{DPxE1? MXzTRW5ITVJ?
EW-16 NID5b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHFTWM2OD1yLkG4O|c4KM7:TR?= M37hfHNCVkeHUh?=
EW-7 NWPkNFFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLCTWM2OD1yLkG4PFgyKM7:TR?= Ml;GV2FPT0WU
NCI-H727 M1T5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P3OGlEPTB;MD6xPVc6PCEQvF2= MlSxV2FPT0WU
LCLC-97TM1 NVLGfFNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\1TWM2OD1yLkKwPVU2KM7:TR?= MmjnV2FPT0WU
NCI-H650 M33iS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfOcmhOUUN3ME2wMlIyOzh2IN88US=> MoLLV2FPT0WU
NCI-H2122 MojrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPFT4hKSzVyPUCuNlMzQTlizszN MWXTRW5ITVJ?
SK-N-DZ NFzDfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMkO2PVgh|ryP NIfaUplUSU6JRWK=
HT-29 NFPGdGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljYTWM2OD1yLkK0NlQ5KM7:TR?= Ml:1V2FPT0WU
LB771-HNC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6xTWM2OD1yLkK1PVE2KM7:TR?= MnrkV2FPT0WU
HT-144 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW5W5JKSzVyPUCuNlYyQTFizszN NGj1TIJUSU6JRWK=
LAN-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPITWM2OD1yLkK2N|Q5KM7:TR?= NVG1NGRWW0GQR1XS
EW-18 NIqzZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jVdWlEPTB;MD6yO|AxOSEQvF2= NVT5eYpTW0GQR1XS
LS-1034 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfOO2FEUUN3ME2wMlI4OTN{IN88US=> M13ub3NCVkeHUh?=
EW-11 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu5TWM2OD1yLkK4OFMzKM7:TR?= M{jZeHNCVkeHUh?=
SNU-C1 NV\p[4hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;S[3dKSzVyPUCuNlk{OTNizszN M2Hrd3NCVkeHUh?=
RS4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\yUWlEPTB;MD6zN|c2QCEQvF2= NXTpOlQ5W0GQR1XS
ES4 NIrJTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNEGwN|gh|ryP MmTmV2FPT0WU
COLO-320-HSR NEDGdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuzOW5KSzVyPUCuOFE{PjhizszN MVjTRW5ITVJ?
NB10 M4HZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Sz[mlEPTB;MD60OVQ{PyEQvF2= M4TMVXNCVkeHUh?=
BFTC-905 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rFc2lEPTB;MD60Olc2QCEQvF2= NVzmWnVkW0GQR1XS
A375 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjXdGlKSzVyPUCuOFc3OTdizszN MYfTRW5ITVJ?
SJRH30 NIXHPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DDNmlEPTB;MD61NFgzOiEQvF2= NIDD[GpUSU6JRWK=
NOS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNUKyOlch|ryP NIfrUmdUSU6JRWK=
SIG-M5 NIPTTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwNUO1OVch|ryP NXfST2xUW0GQR1XS
DOK NVrZcld5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHVepBDUUN3ME2wMlU2PiEQvF2= MVfTRW5ITVJ?
NB69 NFXHVmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofkTWM2OD1yLkW4NlU4KM7:TR?= NEDGeHFUSU6JRWK=
SK-NEP-1 NU\RSoZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwNkCyN|Yh|ryP NWjkdIl7W0GQR1XS
SK-MM-2 M2D4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2RpVKSzVyPUCuOlU1QTFizszN M4HoOHNCVkeHUh?=
NCI-H358 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwNkewPFIh|ryP MmHFV2FPT0WU
RH-1 NFTSUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jndmlEPTB;MD63OFg2QSEQvF2= NWnqfpQ1W0GQR1XS
NH-12 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwN{[wOFYh|ryP MVvTRW5ITVJ?
TE-12 MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwN{[0PFYh|ryP NFXRfHBUSU6JRWK=
COLO-668 NHjyUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\1VHRKSzVyPUCuPFQ3PjZizszN MknPV2FPT0WU
PANC-08-13 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnWOHduUUN3ME2wMlg3Ozd5IN88US=> M1rwSnNCVkeHUh?=
HCC2998 NWPDe4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwOEiyOlMh|ryP NIm1c|NUSU6JRWK=
ABC-1 NVnucnFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwOUCzOVIh|ryP MkjXV2FPT0WU
ES6 NYS3W3pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvHeo1KSzVyPUCuPVExPjZizszN MkTiV2FPT0WU
SNU-387 M1fFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDGS41{UUN3ME2wMlk6Ozl|IN88US=> NW\uRWc1W0GQR1XS
CMK NFriTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HXVmlEPTB;MD65PVkzQSEQvF2= MoPtV2FPT0WU
SJSA-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LFVGlEPTB;MT6wN|Y2OyEQvF2= M13CTHNCVkeHUh?=
SIMA NWfRNYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLL[HNmUUN3ME2xMlA3QDJ3IN88US=> MoLkV2FPT0WU
ES3 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLJOoZuUUN3ME2xMlEzOjl5IN88US=> M{nieXNCVkeHUh?=
IGROV-1 NWPI[2p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMUW0OFQh|ryP MmTtV2FPT0WU
MEL-JUSO NHPiPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof3TWM2OD1zLkG1O|U6KM7:TR?= NVHh[XVvW0GQR1XS
T84 M2DNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMkC5NVQh|ryP MnjxV2FPT0WU
CAL-85-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m5bGlEPTB;MT6yN|E{QCEQvF2= MV7TRW5ITVJ?
RD MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfxOpVKSzVyPUGuNlY1PTVizszN NIq0eWVUSU6JRWK=
TE-8 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DjWGlEPTB;MT6zNVQ3OiEQvF2= MUfTRW5ITVJ?
L-363 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PHZWlEPTB;MT6zOFIxQCEQvF2= M3zKcnNCVkeHUh?=
EKVX M1[2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;6RWtKSzVyPUGuN|Q2PjhizszN MlPZV2FPT0WU
SK-MEL-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwNEi1OVYh|ryP MnLTV2FPT0WU
TGBC24TKB M37FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPyR2hxUUN3ME2xMlUxOTl|IN88US=> NF7vR4VUSU6JRWK=
NCI-H1770 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvSWlEPTB;MT61NVEyOyEQvF2= M3qyTHNCVkeHUh?=
HuH-7 M37jS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pTWM2OD1zLk[wNFk5KM7:TR?= NHPGe45USU6JRWK=
HL-60 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\WPWF6UUN3ME2xMlY3QTJ6IN88US=> NF;2N3dUSU6JRWK=
TE-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfQepBoUUN3ME2xMlcxQTR3IN88US=> MVjTRW5ITVJ?
LC-2-ad M1fWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XSSmlEPTB;MT63N|g5PyEQvF2= NYmyOol[W0GQR1XS
LB647-SCLC NHH2TotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[wTWM2OD1zLke2OVg{KM7:TR?= NIj0[4pUSU6JRWK=
NCI-H2171 NX3OVXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWzRldKSzVyPUGuO|c4OTZizszN M136dHNCVkeHUh?=
SK-PN-DW NW\6NolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm5dG1KSzVyPUGuPVEzQThizszN Ml;6V2FPT0WU
MC-IXC NWfzfIl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37XdmlEPTB;MT65PFk5KM7:TR?= MmP2V2FPT0WU
LS-513 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;XPVFMUUN3ME2yMlA2OzB3IN88US=> M3;XZXNCVkeHUh?=
EW-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL6TWM2OD1{LkC5PFQ1KM7:TR?= MUTTRW5ITVJ?
OPM-2 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HPWGlEPTB;Mj6xNFIh|ryP MmTWV2FPT0WU
LP-1 NFnj[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDyNZVKSzVyPUKuNlU5ODdizszN M3THOXNCVkeHUh?=
LU-134-A NVnVcpBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\QTWM2OD1{LkK3O{DPxE1? MmfUV2FPT0WU
CP66-MEL Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJwMkmwNVQh|ryP Mn61V2FPT0WU
HCC1143 M3K0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvNVHVUUUN3ME2yMlQ2OzZ6IN88US=> M4C0NXNCVkeHUh?=
LOXIMVI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnMTWM2OD1{Lk[wNlEh|ryP M3T2PHNCVkeHUh?=
TE-10 NEnr[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Dlc2lEPTB;Mj63NFg{QCEQvF2= M2roOnNCVkeHUh?=
NCI-H1882 NHrTb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwN{WyNlch|ryP Ml\uV2FPT0WU
CHP-126 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfITY5KSzVyPUKuO|Y{OTdizszN NFLUcIFUSU6JRWK=
NCI-H1623 NEj2T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[1NmlEPTB;Mj65NlAzPCEQvF2= MY\TRW5ITVJ?
GB-1 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJwOUO0NFQh|ryP MoOxV2FPT0WU
RCC10RGB M{XzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwOUWyPFEh|ryP MlrSV2FPT0WU
NCI-H2141 NWrqO2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDPTWM2OD1{Lkm2PFk3KM7:TR?= MUnTRW5ITVJ?
GI-ME-N NGLF[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwMEC1OlUh|ryP M3TQTHNCVkeHUh?=
NCI-H526 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;SUYhKSzVyPUOuNFQxQDVizszN NXXE[mJDW0GQR1XS
NCI-H747 NFHFeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULP[nVDUUN3ME2zMlA1QTl{IN88US=> NYjVfGJYW0GQR1XS
SNU-423 NWrOcoZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwMkCzNVMh|ryP NUm2ZnFtW0GQR1XS
A427 MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWP6enZMUUN3ME2zMlI2Pjl7IN88US=> MYXTRW5ITVJ?
CAL-12T NE\URoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwNEC3NVMh|ryP NW\WT4F1W0GQR1XS
LU-99A MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\QW48yUUN3ME2zMlQ4OTB3IN88US=> MWLTRW5ITVJ?
MS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNwNUO0Nlkh|ryP M{GyWHNCVkeHUh?=
SK-LU-1 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\r[WlEPTB;Mz63OlI6PSEQvF2= MXvTRW5ITVJ?
SW837 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDw[IpXUUN3ME2zMlc3OzN|IN88US=> NUjVWWxwW0GQR1XS
ES8 M1vxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn4dYRzUUN3ME2zMlg{QDd5IN88US=> NVPR[mNVW0GQR1XS
MZ2-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT2OlFKSzVyPUOuPVIxQDZizszN MVvTRW5ITVJ?
TGW M3zabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF23WlhKSzVyPUSuNFE{OTFizszN MofGV2FPT0WU
GP5d MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOyTWM2OD12LkC1N|YzKM7:TR?= MmDyV2FPT0WU
BB49-HNC MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRwMUWyNVMh|ryP NWm3RpFtW0GQR1XS
NB13 NHnabpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ncmlEPTB;ND6yOlg5PyEQvF2= M3L5VXNCVkeHUh?=
NTERA-S-cl-D1 M2TncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTpXWVZUUN3ME20MlI5PjF3IN88US=> MV7TRW5ITVJ?
NCI-H1648 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\uTWM2OD12LkK5PFE6KM7:TR?= M3fjR3NCVkeHUh?=
LCLC-103H Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTHSXFEUUN3ME20MlMzOTl3IN88US=> NGPiZldUSU6JRWK=
LS-411N MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrGSpFrUUN3ME20MlQ1QDh3IN88US=> M1j6WHNCVkeHUh?=
NCI-H1092 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwNEW2PFch|ryP NXTUW3BwW0GQR1XS
PANC-10-05 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLTdGQ{UUN3ME20MlY6QDRizszN M37nbnNCVkeHUh?=
DK-MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjLN|lKSzVyPUSuPFA6OzNizszN MljLV2FPT0WU
OVCAR-5 M2O3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X4PWlEPTB;ND64NVIzPiEQvF2= MWjTRW5ITVJ?
CAL-39 NFTW[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnBTGoxUUN3ME20Mlg4PjdizszN NUj2RpZKW0GQR1XS
TE-441-T NXvP[YRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vOb2lEPTB;ND65NFU{PyEQvF2= NUnBZmhzW0GQR1XS
MOLT-16 NFLQSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LLNmlEPTB;ND65OVI2OyEQvF2= MkfDV2FPT0WU
MCF7 NI\NPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\YTGlEPTB;NT6xOFUyPyEQvF2= MX;TRW5ITVJ?
CAPAN-1 NEXEc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnudpcyUUN3ME21MlI2PzB5IN88US=> NYPieXRuW0GQR1XS
PSN1 NIrU[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknCTWM2OD13LkK3NlM2KM7:TR?= NGT0[HBUSU6JRWK=
NCI-H292 NVrWTXJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LPRWlEPTB;NT6zNFA1PCEQvF2= NWj6PHFHW0GQR1XS
CPC-N MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTVwM{m0NVkh|ryP NX6yS3FOW0GQR1XS
DoTc2-4510 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK0VWVKSzVyPUWuOFU{PzFizszN NFHEOoRUSU6JRWK=
LB1047-RCC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzBVXpKSzVyPUWuOVU6OzNizszN M4D4eXNCVkeHUh?=
MHH-ES-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v6SGlEPTB;NT61PVkxPyEQvF2= NHzyWlVUSU6JRWK=
NMC-G1 NHLYZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;POHltUUN3ME21MlcxOjJ5IN88US=> NUS1e4U{W0GQR1XS
SW1710 M3PxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrYTWM2OD13Lke0O|UyKM7:TR?= MojzV2FPT0WU
YAPC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rHOWlEPTB;NT63OlIxOSEQvF2= NH3UT5lUSU6JRWK=
22RV1 NWDvUIoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f5bGlEPTB;NT64NFAyQSEQvF2= NYnVVYV7W0GQR1XS
COLO-679 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHVb4FKSzVyPUWuPFg6PDhizszN NULoUItVW0GQR1XS
TCCSUP MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTOUYwzUUN3ME21Mlk{OjV7IN88US=> MUDTRW5ITVJ?
C2BBe1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TXPWlEPTB;NT65N|k4KM7:TR?= NFPlSGtUSU6JRWK=
TE-15 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDNTWM2OD14LkC2OlA2KM7:TR?= M{HWOHNCVkeHUh?=
SCLC-21H NF:3WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXGTWM2OD14LkGwPFQ{KM7:TR?= Ml3PV2FPT0WU
EoL-1-cell MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jiRWlEPTB;Nj6xOlU3OyEQvF2= NGnGZmpUSU6JRWK=
NKM-1 M2rw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZwMU[3NUDPxE1? MWHTRW5ITVJ?
NCI-H1304 M3W0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof0TWM2OD14LkK3OFI5KM7:TR?= MVLTRW5ITVJ?
NB6 NH7JdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTZwMkm2NlIh|ryP M4LDVXNCVkeHUh?=
NALM-6 M2S3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\NU2lEPTB;Nj6zN|I{KM7:TR?= MnzwV2FPT0WU
NCI-H522 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTZwM{OzNFYh|ryP MmLDV2FPT0WU
MV-4-11 NIDOO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP6b2VKSzVyPU[uN|cxPzlizszN MWPTRW5ITVJ?
LB2241-RCC NHP5TVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LVZ2lEPTB;Nj6zPFY3PyEQvF2= NXXBVmc5W0GQR1XS
NCI-H1417 NIPvNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK5OI1KSzVyPU[uOFA5PDdizszN NUm3bmtiW0GQR1XS
HT-1197 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwNUexNlIh|ryP MW\TRW5ITVJ?
P30-OHK M1\DZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL2NYJKSzVyPU[uOlI4PyEQvF2= NGi4WG9USU6JRWK=
ALL-PO NUDVRlF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTZwN{G5NVYh|ryP MXfTRW5ITVJ?
OVCAR-4 M4f1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfoTWM2OD14Lke1OFA2KM7:TR?= M1jUeXNCVkeHUh?=
HCC2157 NH;BT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon1TWM2OD14Lke3OFc2KM7:TR?= MXTTRW5ITVJ?
NCI-H838 NVizeoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\vcHEzUUN3ME22Mlk3PDlizszN Mnj1V2FPT0WU
NCI-H1299 NYXsSIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvSmlEPTB;Nj65O|A6KM7:TR?= NV:3VZlIW0GQR1XS
SW954 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrHblBKSzVyPUeuNlAxPjhizszN NX3EfWRLW0GQR1XS
NCI-H441 MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPITFNFUUN3ME23MlM1ODZ3IN88US=> MYPTRW5ITVJ?
SK-MEL-2 NU\PWZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PrUmlEPTB;Nz60PFM4OyEQvF2= M1jQNXNCVkeHUh?=
KARPAS-45 M4\DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTUTWM2OD15Lk[1PVI6KM7:TR?= NFvZZlBUSU6JRWK=
CAL-54 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknuTWM2OD15LkiyPVc4KM7:TR?= NV3nSIE5W0GQR1XS
KYSE-180 NEewb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTobXFyUUN3ME23Mlg5QTRzIN88US=> NInRRoZUSU6JRWK=
NCI-H187 NWPqSFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmyTGVKSzVyPUeuPVU6PDdizszN M1i0NXNCVkeHUh?=
RT-112 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRThwMEm2O|ch|ryP M1rRenNCVkeHUh?=
NCI-H1437 M{\JN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXnSWFKSzVyPUiuNFk4QTVizszN NUXNZ4NoW0GQR1XS
SNU-449 NWPHbnduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofGTWM2OD16LkK4NlczKM7:TR?= M2T6NHNCVkeHUh?=
HCC1187 NUnMO5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRThwMkmzPVEh|ryP NHHmTmJUSU6JRWK=
NCI-H2030 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRThwM{e3NVQh|ryP MVXTRW5ITVJ?
HuO-3N1 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG3O3ZKSzVyPUiuN|c5PDRizszN Mn7FV2FPT0WU
COLO-792 M37Eb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TqWGlEPTB;OD60NVUzPyEQvF2= MVjTRW5ITVJ?
MIA-PaCa-2 NXrNcGdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fk[mlEPTB;OD64OVUxQCEQvF2= NF\6VW1USU6JRWK=
SK-N-FI MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjGSnNKSzVyPUmuNFQzPSEQvF2= MXPTRW5ITVJ?
MMAC-SF M32yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zOcmlEPTB;OT6wPVc2OSEQvF2= MUHTRW5ITVJ?
NCI-H28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW4[Gx2UUN3ME25MlExPDZ7IN88US=> M1PYSXNCVkeHUh?=
ETK-1 NYXiNFQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7IT3BKSzVyPUmuNlk6PzRizszN NHzPcXlUSU6JRWK=
NCI-H1993 NEji[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTlwNESyOlEh|ryP MUnTRW5ITVJ?
no-11 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0TWM2OD17LkS3NVIh|ryP NEfRfVNUSU6JRWK=
ChaGo-K-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTxTWM2OD17LkWxOVg{KM7:TR?= Mm\FV2FPT0WU
NCCIT NH3vUmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsNVJKSzVyPUmuOVMyPjlizszN MYDTRW5ITVJ?
SAS NVyzXYNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLoTWM2OD1zMD6yOFgh|ryP NYDFcWl6W0GQR1XS
A673 MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD1zMD6zO|A1KM7:TR?= NX3w[oJ1W0GQR1XS
NCI-H1522 M2[2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jlUGlEPTB;MUCuN|cxPyEQvF2= MnPYV2FPT0WU
NCI-H810 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHLdZl4UUN3ME2xNE4{QTB5IN88US=> Ml3QV2FPT0WU
IST-MES1 NGnKXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HlT2lEPTB;MUCuOFU3PCEQvF2= NYrpNVZlW0GQR1XS
GR-ST NEjTZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:xTWM2OD1zMD61NFI1KM7:TR?= MlOwV2FPT0WU
SUP-T1 NEnxWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7tTWM2OD1zMD63N|E4KM7:TR?= NYXC[4k{W0GQR1XS
NB5 MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofmTWM2OD1zMD65NFIzKM7:TR?= MWHTRW5ITVJ?
MZ1-PC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPCTWM2OD1zMD65OVcyKM7:TR?= M1;0ZnNCVkeHUh?=
SK-CO-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LzXmlEPTB;MUCuPVk{OSEQvF2= NHLNbIdUSU6JRWK=
Capan-2 NIrVPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrtfW1nUUN3ME2xNU4{OTl6IN88US=> NIjwWZBUSU6JRWK=
697 M{HoU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHkTWM2OD1zMT62O|U4KM7:TR?= M2i5Z3NCVkeHUh?=
REH NYG1XYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrnTWM2OD1zMT63OFUyKM7:TR?= M4PJcnNCVkeHUh?=
GI-1 NXnxS3ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXPW|BKSzVyPUGxMlg3OTVizszN MmDsV2FPT0WU
BB65-RCC NUmzO25oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHxTWM2OD1zMj6wPVE3KM7:TR?= MX3TRW5ITVJ?
NCI-H1651 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF{LkK0O|gh|ryP NXXVOpE2W0GQR1XS
NCI-H1618 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPYe2piUUN3ME2xNk4{QTd4IN88US=> NWHzSndWW0GQR1XS
NCI-H2081 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHkZ5QzUUN3ME2xNk43OTRzIN88US=> MU\TRW5ITVJ?
GCIY NGXKNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF{LkeyNVMh|ryP NFLmXY5USU6JRWK=
NY MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuzTWM2OD1zMz6wOlQ{KM7:TR?= MnTrV2FPT0WU
PANC-03-27 NUP1VndmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hwe2lEPTB;MUOuNFgxPyEQvF2= M4XyOXNCVkeHUh?=
BHY NES1bI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfNdZczUUN3ME2xN{4zOTJzIN88US=> MX\TRW5ITVJ?
SK-OV-3 NH;Hd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDN[o5KSzVyPUGzMlM4PjNizszN M1TaZXNCVkeHUh?=
5637 NVvuRo1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF|Lke3OVkh|ryP Mk[2V2FPT0WU
LC-1F NGfQ[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOzRXIzUUN3ME2xOE4xOzV4IN88US=> M{jRR3NCVkeHUh?=
SNB75 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXUdnZKSzVyPUG0MlA{QDNizszN NWXWTWY2W0GQR1XS
CHP-212 M{XNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF2LkC0OlQh|ryP NUHJeoZnW0GQR1XS
HT-1376 M{Pwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\qTWhKSzVyPUG0MlEyOjZizszN MmXyV2FPT0WU
MONO-MAC-6 NWDpWGloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF2LkG1NFIh|ryP NFHIPIdUSU6JRWK=
CA46 M{S5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXPXpNTUUN3ME2xOE4yQDJ5IN88US=> NHfhSoRUSU6JRWK=
SCC-15 NYHje4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF2LkW1PFMh|ryP Mm\DV2FPT0WU
ATN-1 M2[wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF2Lk[2Nlch|ryP NWjqU4pRW0GQR1XS
NCI-H2405 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXFRoZ3UUN3ME2xOE45OTV5IN88US=> MYrTRW5ITVJ?
NCI-H716 NIC1cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vGWmlEPTB;MUSuPFQ6OyEQvF2= NHXFSnFUSU6JRWK=
SW620 NXj6eVZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT0ZXZpUUN3ME2xOE46ODF2IN88US=> MnzYV2FPT0WU
NCI-H226 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r6W2lEPTB;MUSuPVA5PSEQvF2= NXHud5dEW0GQR1XS
SW962 NXHXOJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF2Lkm0N|Ih|ryP NWTybWZEW0GQR1XS
KYSE-150 NEHGeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF2Lkm1OUDPxE1? MYPTRW5ITVJ?
OCUB-M Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjjWmxKSzVyPUG0Mlk5QDNizszN MlTlV2FPT0WU
ES7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD1zNT6wPVg1KM7:TR?= NUj6RW9PW0GQR1XS
SW1463 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF3LkSyNlMh|ryP M365NXNCVkeHUh?=
CAKI-1 MkG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LLd2lEPTB;MUWuOVM1PiEQvF2= NXTrTIIzW0GQR1XS
MKN28 NUTPV|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\xZ2lEPTB;MUWuOVQ4QSEQvF2= NV\xWlROW0GQR1XS
SW13 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfwTI9FUUN3ME2xOU43OThizszN M{m4cnNCVkeHUh?=
A3-KAW Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC1TWM2OD1zNT65Olk4KM7:TR?= MYnTRW5ITVJ?
LU-65 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLDTWM2OD1zNT65O|Y5KM7:TR?= MnHxV2FPT0WU
Calu-1 M2L3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXroXYY5UUN3ME2xOk4xOzZ6IN88US=> MoHEV2FPT0WU
ST486 NVO2N5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfn[JFbUUN3ME2xOk4xPDNzIN88US=> NHrJflFUSU6JRWK=
BB30-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfhTWM2OD1zNj6xNlQ3KM7:TR?= MXrTRW5ITVJ?
EGI-1 M2H5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjiTWM2OD1zNj60OFYh|ryP MkS1V2FPT0WU
SH-4 NEWyRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrFT2lKSzVyPUG2MlQ4OzFizszN MUTTRW5ITVJ?
MN-60 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjK[mNIUUN3ME2xO{4zOjl5IN88US=> NXjRN4ZUW0GQR1XS
MPP-89 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnsUXFmUUN3ME2xO{4zPDV7IN88US=> MYHTRW5ITVJ?
A2780 NH3P[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF5LkSxN|kh|ryP MkXOV2FPT0WU
Daoy M4rRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF5LkS2PVUh|ryP NWKzUYFsW0GQR1XS
NCI-H2126 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF5LkS3O|Eh|ryP NFHOSJpUSU6JRWK=
NCI-H1563 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfmTWM2OD1zNz60PVE4KM7:TR?= MYnTRW5ITVJ?
8-MG-BA M3LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HSc2lEPTB;MUeuOlY1QCEQvF2= NV7ETZpnW0GQR1XS
786-0 MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr5Tm9KSzVyPUG3Mlg{PTNizszN M1r4W3NCVkeHUh?=
AM-38 M3jMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPOb3U4UUN3ME2xO{46OzB4IN88US=> Mof3V2FPT0WU
COLO-824 M2XKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\STWM2OD1zOD60OFM3KM7:TR?= MW\TRW5ITVJ?
SK-MEL-30 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2myPGlEPTB;MUiuOVA5OiEQvF2= NGHlRZhUSU6JRWK=
CESS NYLVc3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XtcWlEPTB;MUiuO|YxQSEQvF2= NHj1[oZUSU6JRWK=
BL-70 NYnQVWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvlUoJKSzVyPUG4MlgyPTZizszN NYTHbmtpW0GQR1XS
NCI-H2170 NF;EXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\zd5JJUUN3ME2xPE46OTd7IN88US=> NULkSHBVW0GQR1XS
HT-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF6Lkm4N{DPxE1? M2jNd3NCVkeHUh?=
BOKU M3HJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TEPWlEPTB;MUmuNFM5OSEQvF2= NUjsV3V2W0GQR1XS
HPAF-II M130cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzwTWM2OD1zOT6zNFE2KM7:TR?= M37yWHNCVkeHUh?=
KGN M2rIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPNOZp2UUN3ME2xPU41PzZ3IN88US=> NHfUPJVUSU6JRWK=
MC-CAR NXzZZYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzxO2YxUUN3ME2xPU43OzF|IN88US=> MonqV2FPT0WU
BHT-101 M3fWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH65Z4xKSzVyPUG5Mlc4PyEQvF2= NHizPYZUSU6JRWK=
SW1783 NWflZlRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvfGlEPTB;MUmuO|gxPiEQvF2= NIHVNpRUSU6JRWK=
KP-N-YN MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M360R2lEPTB;MkCuNFI3OiEQvF2= M1nTNXNCVkeHUh?=
LU-165 M4DZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonmTWM2OD1{MD61OVcyKM7:TR?= Ml;MV2FPT0WU
GOTO NE\0fIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXrTWM2OD1{MD62OFUyKM7:TR?= M1j1TXNCVkeHUh?=
EFM-19 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPicnZmUUN3ME2yNU4xPzF4IN88US=> MYXTRW5ITVJ?
CTV-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL1TWM2OD1{MT6xNFU1KM7:TR?= MU\TRW5ITVJ?
HEL NIHKTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPScpJKSzVyPUKxMlQzOTZizszN NFjhc2tUSU6JRWK=
SNU-C2B NI\tN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\1R4VvUUN3ME2yNU41OjZizszN MX\TRW5ITVJ?
ECC4 NH\LNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXOeFVKSzVyPUKxMlcxPyEQvF2= NH24RVVUSU6JRWK=
NEC8 M3zPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfuUotKSzVyPUKxMlg{PjhizszN NYnwWmdTW0GQR1XS
KMOE-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjSSW5KSzVyPUKxMlg6OjFizszN NWqxfWlGW0GQR1XS
NCI-H524 NWXGbplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULjT3BLUUN3ME2yNk4xQDB6IN88US=> M3\wOXNCVkeHUh?=
WSU-NHL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDmTWM2OD1{Mj6xOVc4KM7:TR?= MWXTRW5ITVJ?
SF126 M4H2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLQXnJQUUN3ME2yNk4zPDZ7IN88US=> MmjSV2FPT0WU
HOP-92 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXZVm5KSzVyPUKyMlMyPjdizszN NVrjfXdiW0GQR1XS
CTB-1 MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJ{LkS2O|ch|ryP MnrVV2FPT0WU
KYSE-270 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDGTWM2OD1{Mj65N|U4KM7:TR?= M2OzdXNCVkeHUh?=
SK-MEL-24 NX;KXWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\ETWM2OD1{Mz6xPFch|ryP MkfSV2FPT0WU
Calu-3 NECwVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\XTWM2OD1{Mz6yNVI5KM7:TR?= NU\lTWh[W0GQR1XS
GAMG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJ|LkKzOlch|ryP NIryXW5USU6JRWK=
SW1573 NV\ZblJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n1UmlEPTB;MkOuO|QyPSEQvF2= NH;LenJUSU6JRWK=
MHH-NB-11 NGDEdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrZYNNUUN3ME2yOE4xOTl2IN88US=> MonSV2FPT0WU
TK10 M3TmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PJVGlEPTB;MkSuOVAyOyEQvF2= M3Lld3NCVkeHUh?=
LB373-MEL-D NWTabXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDwTWM2OD1{ND62NFY1KM7:TR?= M{XwNXNCVkeHUh?=
KALS-1 NHrOeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ2LkezNlch|ryP NELkSZlUSU6JRWK=
HUTU-80 NIXORnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\jb2VYUUN3ME2yOU45ODN{IN88US=> M2\5[XNCVkeHUh?=
HuP-T3 M4fIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ4LkG2O|Qh|ryP NXrlNmNzW0GQR1XS
OE19 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW5UIJKSzVyPUK2MlIyPTNizszN NULyXmx4W0GQR1XS
J82 NIfRS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIToSHlKSzVyPUK2MlI1PzFizszN MnHsV2FPT0WU
DU-4475 M3\MeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHGTIVGUUN3ME2yOk4{QDF7IN88US=> NH30OXpUSU6JRWK=
DMS-53 NIWxSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHsd2hkUUN3ME2yOk42OTN6IN88US=> NHv4XW1USU6JRWK=
COLO-741 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS0TWM2OD1{Nj64N|Q1KM7:TR?= NHHV[YtUSU6JRWK=
SW48 NIKweZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnUdXVKSzVyPUK2Mlg5OiEQvF2= NYnib5g1W0GQR1XS
IGR-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37uWWlEPTB;Mk[uPVM{PCEQvF2= MnXoV2FPT0WU
639-V NG\UfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTJTXZ{UUN3ME2yO{4xOjR3IN88US=> NWiwOHdbW0GQR1XS
LK-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK1R2RKSzVyPUK3MlQyPDFizszN MWrTRW5ITVJ?
NCI-H2347 NEm3O|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorRTWM2OD1{Nz65Olk6KM7:TR?= M4fvR3NCVkeHUh?=
NCI-H2228 NF;nXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor5TWM2OD1{OD6wPVA2KM7:TR?= NXnNXpI6W0GQR1XS
LS-123 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtdHJKSzVyPUK4MlEzPjJizszN MVvTRW5ITVJ?
U031 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17CXmlEPTB;MkiuNlUzKM7:TR?= NGHSV2xUSU6JRWK=
NCI-H1792 NYHoUGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ6LkS3NlEh|ryP NF\ie4xUSU6JRWK=
NCI-H2087 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ6Lke1OVIh|ryP MXjTRW5ITVJ?
NCI-H2342 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ7LkWyNFgh|ryP M{T4WXNCVkeHUh?=
SW626 M{TGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L5SWlEPTB;MkmuO|U3KM7:TR?= NXLC[HhpW0GQR1XS
LB2518-MEL NEL5UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrnTWM2OD1{OT64NVUh|ryP M1r3b3NCVkeHUh?=
RXF393 NIrLR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNyLkC5OVIh|ryP M{m1PXNCVkeHUh?=
LC4-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3WJhKSzVyPUOwMlMxQTJizszN M4rweXNCVkeHUh?=
NCI-H1694 NX\VZ3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHSTWM2OD1|MD62OlI1KM7:TR?= Mlu3V2FPT0WU
K5 NInjem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X1OGlEPTB;M{CuPVcxOiEQvF2= NFLJS4dUSU6JRWK=
HDLM-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\UT2lEPTB;M{CuPVczPSEQvF2= NFL0dZVUSU6JRWK=
BCPAP MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HVWGlEPTB;M{GuPFM4QSEQvF2= MlHpV2FPT0WU
BC-3 NXXHUlBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSy[ItMUUN3ME2zNk4yPDB|IN88US=> MX;TRW5ITVJ?
LB996-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTN{LkKzOVgh|ryP Mlj5V2FPT0WU
NCI-H2009 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzvTWM2OD1|Mj60PVgyKM7:TR?= NH7qbotUSU6JRWK=
HTC-C3 M4[5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX2TWM2OD1|Mz63OVE6KM7:TR?= Ml;EV2FPT0WU
LAMA-84 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN2LkS0NFch|ryP M4izenNCVkeHUh?=
CCRF-CEM NVXIV4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmxWFJKSzVyPUO0MlU4OTVizszN MVTTRW5ITVJ?
AN3-CA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH3TWM2OD1|NT6wOVY5KM7:TR?= NWnYOHQyW0GQR1XS
NCI-H1734 NV;RWpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVriUGs{UUN3ME2zOU4zPTZzIN88US=> NXqwT3drW0GQR1XS
Ca-Ski Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTETWM2OD1|NT60NVAyKM7:TR?= MXnTRW5ITVJ?
U-266 MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL0TWM2OD1|NT62NVE1KM7:TR?= MoHjV2FPT0WU
SBC-5 NFrmR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHP[4RKSzVyPUO1Mlc4QDFizszN NH;BPXVUSU6JRWK=
GT3TKB NWi5d4hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnOTm5KSzVyPUO3MlEyPSEQvF2= MoCwV2FPT0WU
MDA-MB-175-VII NUe2SlZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfrSFZKSzVyPUO3MlIzPDhizszN MmnnV2FPT0WU
PFSK-1 NV;kSJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID3fWZKSzVyPUO3MlI1OzVizszN MlLHV2FPT0WU
IMR-5 NGTifXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPwdJRKSzVyPUO3MlI1QDdizszN NYD6OIZ[W0GQR1XS
Daudi NUfkdHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\DUY57UUN3ME2zO{4{PTl5IN88US=> M37FcnNCVkeHUh?=
A498 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XGOGlEPTB;M{euO|IyQCEQvF2= M2PBUnNCVkeHUh?=
SCC-4 M{XzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzrTHBqUUN3ME2zO{44QDR|IN88US=> NGjrVXhUSU6JRWK=
COLO-680N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknBTWM2OD1|OD6yPFg2KM7:TR?= MYrTRW5ITVJ?
SK-MES-1 NF3hUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTvRndKSzVyPUO4MlMzOTVizszN MoHoV2FPT0WU
SR NXnLeoxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTN6LkW0PVUh|ryP MnrQV2FPT0WU
LNCaP-Clone-FGC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW0OlFKSzVyPUO4MlU3OzdizszN MWLTRW5ITVJ?
SK-HEP-1 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XjZWlEPTB;M{iuO|gzOiEQvF2= NYDWNoh5W0GQR1XS
BPH-1 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm2UmdQUUN3ME2zPE45OzJ7IN88US=> MYPTRW5ITVJ?
NCI-H1755 NEPFUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm3NIlKSzVyPUO5MlU5OTdizszN MYnTRW5ITVJ?
LXF-289 M2CwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljMTWM2OD1|OT64NFg1KM7:TR?= NHjLOo9USU6JRWK=
SW1088 NV24XWZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvUTGR4UUN3ME20NE4zOTB5IN88US=> NV\WTWFWW0GQR1XS
MOLT-4 NWHPfGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jOcmlEPTB;NECuNlkxOSEQvF2= NEnhWWFUSU6JRWK=
AsPC-1 MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnmOFE2UUN3ME20NE41PTh|IN88US=> MnK0V2FPT0WU
HOP-62 M{GzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjsbXlKSzVyPUSwMlY2PjhizszN MlTnV2FPT0WU
A172 Mli5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fIVmlEPTB;NECuPFUyOSEQvF2= NV3BU3l2W0GQR1XS
SN12C NIPjbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\HeHFCUUN3ME20NE46Ozh3IN88US=> NHnzS|ZUSU6JRWK=
MDA-MB-231 NXzVdmhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPZTWM2OD12MD65PFk5KM7:TR?= MlrmV2FPT0WU
RPMI-2650 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjTcW9KSzVyPUSxMlE2QTNizszN MnXkV2FPT0WU
KYSE-140 NFOwUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTRzLkixNlMh|ryP M{\QS3NCVkeHUh?=
KINGS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HzTmlEPTB;NEKuOFY6PyEQvF2= MXTTRW5ITVJ?
HSC-3 M3z6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfWUJN5UUN3ME20Nk43PjZzIN88US=> MlHmV2FPT0WU
PC-14 M3jWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3N2lEPTB;NEOuNVg5OiEQvF2= MnTnV2FPT0WU
COR-L105 NVnzO2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\s[2lEPTB;NEOuOlUxOiEQvF2= NV[2[JN5W0GQR1XS
BE-13 M2XxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXWUZRiUUN3ME20OE4zOzdzIN88US=> MXrTRW5ITVJ?
NCI-H661 M37XRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;wTWM2OD12ND6yPVU5KM7:TR?= NEDafm5USU6JRWK=
IST-MEL1 NFXGfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\3TWM2OD12ND6zOVk6KM7:TR?= MWTTRW5ITVJ?
HCC1806 NWTtUGZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljJTWM2OD12ND61PFc{KM7:TR?= NFraRlVUSU6JRWK=
COLO-800 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLJfJpSUUN3ME20OE45PDV|IN88US=> NYTKTJpJW0GQR1XS
IST-SL2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfPTWM2OD12NT6xNlQ4KM7:TR?= M2DKdnNCVkeHUh?=
8305C NHHKTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Pme2lEPTB;NEWuN|A6KM7:TR?= MW\TRW5ITVJ?
UACC-62 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR4LkK4O|Uh|ryP M3OzbHNCVkeHUh?=
COR-L23 NYPkc3VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTR5LkG5PUDPxE1? NEnzOpNUSU6JRWK=
EFE-184 M3vr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Pvb2lEPTB;NEeuN|g5KM7:TR?= NWrpfnd1W0GQR1XS
DMS-114 M3f1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR5LkSxOFkh|ryP M1fYVHNCVkeHUh?=
KYSE-520 NV;VeHA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR6LkWzNVUh|ryP MmTqV2FPT0WU
SNG-M MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPBPYRKSzVyPUS5MlQ{PCEQvF2= MXvTRW5ITVJ?
A2058 NILmV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PPemlEPTB;NEmuOFg5PSEQvF2= NGrGRXFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID